Evaluation of the CareStart™ glucose-6-phosphate dehydrogenase (G6PD) rapid diagnostic test in the field settings and assessment of perceived risk from primaquine at the community level in Cambodia.
Bertha WojnarskiChanthap LonDarapiseth SeaSomethy SokSabaithip SriwichaiSoklyda ChannSohei HomThreechada BoonchanSokna LyChandara SokSamon NouPheaktra OungNareth KongVannak PheapKhengheang ThayVy DaoWorachet KuntawunginnMitra FeldmanPanita GosiNillawan BuathongMali IttiverakulNichapat UthaimongkolRekol HuyMichele SpringDysoley LekPhilip SmithMark M FukudaMariusz WojnarskiPublished in: PloS one (2020)
This study demonstrated ability of medical staff with different background to accurately use CareStart™ RDT to identify G6PDd in male patients, which may enable safer prescribing of primaquine; however, pharmacovigilance is required to address possible G6PDd misclassifications.